Mobile

A study to test the safety, tolerability and ability to maintain HIV suppression of switching from a tenofovir disoproxil fumarate (TDF) containing regimen to elvitegravir/cobicistat/emtricitabine/ te...

Update Il y a 4 ans
Reference: EUCTR2015-002712-32

A study to test the safety, tolerability and ability to maintain HIV suppression of switching from a tenofovir disoproxil fumarate (TDF) containing regimen to elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) in the HIV-1 infected subjects aged ≥ 60 years who are virologically suppressed

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

-To evaluate the safety of E/C/F/TAF relative to unchanged current antiretroviral therapy (ART) by assessing spine and hip bone mineral density (BMD) measured at Week 48 in virologically-suppressed, HIV-1 infected subjects aged ≥ 60 years

Inclusion criteria

  • Human Immunodeficiency Virus (HIV-1) Infection

Links